M Crowther

Summary

Country: UK

Publications

  1. doi request reprint Antidotes for novel oral anticoagulants: current status and future potential
    Mark Crowther
    From the Department of Haematology, Worcestershire Royal Hospital, Worcester, United Kingdom M C and Department of Haematology, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada M A C
    Arterioscler Thromb Vasc Biol 35:1736-45. 2015
  2. doi request reprint Being underweight may reduce your ability to mobilise peripheral blood stem cells
    Mark Crowther
    Department of Haematology, Worcestershire Royal Hospital, Worcester, UK
    Transfus Apher Sci 43:365-7. 2010
  3. doi request reprint Intensity of warfarin coagulation in the antiphospholipid syndrome
    Mark Crowther
    Division of Hematology and Thromboembolism, McMaster University, St Joseph s Hospital, 50 Charlton Ave, East Hamilton, Ontario, Canada
    Curr Rheumatol Rep 12:64-9. 2010
  4. doi request reprint Hot topics in parenteral nutrition. A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy
    Mark Crowther
    Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, UK
    Proc Nutr Soc 68:269-73. 2009
  5. doi request reprint Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation
    M Crowther
    Department of Haematology, Ward 16, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZD, UK
    Bone Marrow Transplant 44:413-25. 2009
  6. doi request reprint Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism
    M J Kovacs
    Department of Hematology, London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada
    J Thromb Haemost 8:1926-32. 2010
  7. doi request reprint Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
  8. doi request reprint Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis
    D Cook
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Crit Care 24:168-75. 2009
  9. ncbi request reprint Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Pharmacoeconomics 24:593-607. 2006
  10. ncbi request reprint Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial
    Francesco Dentali
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Ann Pharmacother 40:1241-7. 2006

Detail Information

Publications29

  1. doi request reprint Antidotes for novel oral anticoagulants: current status and future potential
    Mark Crowther
    From the Department of Haematology, Worcestershire Royal Hospital, Worcester, United Kingdom M C and Department of Haematology, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada M A C
    Arterioscler Thromb Vasc Biol 35:1736-45. 2015
    ..Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal. These agents are currently in premarketing studies. ..
  2. doi request reprint Being underweight may reduce your ability to mobilise peripheral blood stem cells
    Mark Crowther
    Department of Haematology, Worcestershire Royal Hospital, Worcester, UK
    Transfus Apher Sci 43:365-7. 2010
    ..Therefore being underweight may reduce a patient's ability to mobilise peripheral blood stem cells and, if confirmed, improving nutritional status may reduce the number of patients who fail to mobilise...
  3. doi request reprint Intensity of warfarin coagulation in the antiphospholipid syndrome
    Mark Crowther
    Division of Hematology and Thromboembolism, McMaster University, St Joseph s Hospital, 50 Charlton Ave, East Hamilton, Ontario, Canada
    Curr Rheumatol Rep 12:64-9. 2010
    ..Care must be taken with all anticoagulants because of the increased risk of bleeding. Several other strategies are available if warfarin fails, including the addition of aspirin, increasing the warfarin target range, and use of heparin...
  4. doi request reprint Hot topics in parenteral nutrition. A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy
    Mark Crowther
    Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, UK
    Proc Nutr Soc 68:269-73. 2009
    ..host disease, while intravenous glutamine may reduce infections but at the expense of an increased relapse rate. Good-quality studies are required in this area...
  5. doi request reprint Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation
    M Crowther
    Department of Haematology, Ward 16, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZD, UK
    Bone Marrow Transplant 44:413-25. 2009
    ..In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects...
  6. doi request reprint Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism
    M J Kovacs
    Department of Hematology, London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada
    J Thromb Haemost 8:1926-32. 2010
    ....
  7. doi request reprint Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    Sam Schulman
    Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada
    N Engl J Med 361:2342-52. 2009
    ..The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism...
  8. doi request reprint Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis
    D Cook
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Crit Care 24:168-75. 2009
    ....
  9. ncbi request reprint Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis
    George Dranitsaris
    Augmentium Pharma Consulting, Toronto, Ontario, Canada
    Pharmacoeconomics 24:593-607. 2006
    ..002). A Canadian pharmacoeconomic analysis was conducted to measure the economic value of dalteparin for this indication...
  10. ncbi request reprint Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial
    Francesco Dentali
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Ann Pharmacother 40:1241-7. 2006
    ..Cyclooxygenase-2 selective NSAIDs such as celecoxib may be less likely to promote gastrointestinal bleeding; however, there are concerns that they could potentiate the anticoagulation effect of warfarin...
  11. ncbi request reprint Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials
    Francesco Dentali
    Department of Medicine, McMaster University, and St Joseph s Healthcare, Hamilton, Ontario, Canada
    Arch Intern Med 167:117-24. 2007
    ..We performed a systematic review and meta-analysis of randomized controlled trials comparing these 2 treatment strategies (combined aspirin-OAC therapy vs OAC therapy alone) to assess the therapeutic benefits and risks...
  12. doi request reprint Assessment of von Willebrand disease as a risk factor for primary postpartum haemorrhage
    Y L Chee
    Department of Haematology, Foresterhill Health Campus, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK
    Haemophilia 18:593-7. 2012
    ..41 (95% CI 1.07-10.9) P = 0.038). VWD in itself may not be a significant risk factor for PPH, however, women known to have VWD predelivery may represent an at risk sub-group...
  13. doi request reprint Serum lipoprotein (a) levels in patients with first unprovoked venous thromboembolism is not associated with subsequent risk of recurrent VTE
    M A Rodger
    Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Clinical Epidemiology Unit, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ottawa, Ontario, Canada
    Thromb Res 126:222-6. 2010
    ..We sought to determine if serum Lp(a) levels in patients with unprovoked VTE who discontinue anticoagulants after 5 to 7 months of therapy predict VTE recurrence in a prospective cohort study...
  14. doi request reprint A guide to GRADE guidelines for the readers of JTH
    G Guyatt
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
    J Thromb Haemost 11:1603-8. 2013
    ....
  15. ncbi request reprint Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study
    D Cook
    Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Crit Care 16:161-6. 2001
    ..3, P =.001). CONCLUSIONS: VTE prevention for surgical ICU patients within the first postoperative week appear to be individualized, and influenced by current and future risks of thrombosis and bleeding...
  16. doi request reprint Preventing and managing bleeding complications in anticoagulated patients: a case based approach
    Mark Crowther
    Division of Hematology, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 4A6
    Thromb Res 123:S42-5. 2008
    ..The paper is "case based" and narrative since there is little evidence to guide practice in this area...
  17. pmc Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
    Deborah Cook
    Department of Medicine, 1200 Main Street, McMaster University, Hamilton, Canada
    Crit Care 12:R32. 2008
    ..The objective of the present study was to evaluate the prevalence, incidence and predictors of DVT and the incidence of bleeding in intensive care unit (ICU) patients with estimated creatinine clearance <30 ml/min...
  18. doi request reprint Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study
    Gregoire Le Gal
    Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
    Thromb Haemost 104:498-503. 2010
    ..The risk of recurrent VTE is low in women after a first otherwise unprovoked oestrogen-associated VTE. However, this risk is not significantly lower than in women whose VTE was not related to oestrogen use...
  19. doi request reprint Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations
    Marco P Donadini
    Division of Hematology and Thromboembolism, St Joseph s Hospital, McMaster University, Hamilton, ON, Canada
    Hematol Oncol Clin North Am 24:669-76, vii. 2010
    ..At present, there is no evidence to support or refute specific treatment strategies for primary prophylaxis of thrombosis...
  20. ncbi request reprint Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease
    Uma H Athale
    Division of Hematology Oncology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada
    Br J Haematol 129:803-10. 2005
    ..Age-related risk may partly reflect the effect of ALL-risk stratification. Higher dose steroids combined with ASP may lead to an increased risk of TE in HR patients...
  21. doi request reprint Antiphospholipid antibodies in critical illness
    Francesco Dentali
    St Joseph s Hospital, Hamilton, Ontario, Canada
    Crit Care Med 38:S51-6. 2010
    ..The optimal treatment of other clinical manifestations of antiphospholipid syndrome needs to be addressed in well-designed prospective studies...
  22. ncbi request reprint Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors
    Deborah Cook
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Crit Care Med 33:1565-71. 2005
    ..The objective was to determine the prevalence, incidence, and risk factors for proximal lower extremity deep venous thrombosis among critically ill medical-surgical patients...
  23. doi request reprint Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review
    Christine Ribic
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    J Crit Care 24:197-205. 2009
    ..The study aimed to systematically review the effect of low-molecular-weight heparin (LMWH) thromboprophylaxis in medical-surgical critically ill patients in the intensive care unit...
  24. ncbi request reprint New anticoagulants: an update
    Mark Crowther
    Division of Hematology, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada
    Clin Adv Hematol Oncol 2:743-9. 2004
    ....
  25. doi request reprint Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study
    James Douketis
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Arch Intern Med 168:1805-12. 2008
    ..To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency...
  26. ncbi request reprint Low molecular weight heparin and bleeding in patients with chronic renal failure
    Mark Crowther
    St Joseph s Hospital, Hamilton, Ontario, Canada
    Curr Opin Pulm Med 13:409-13. 2007
    ..Consequently, care should be employed when LMWH is administered to patients with impaired renal function as reduced clearance and bioaccumulation may cause bleeding...
  27. pmc Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
    Mark Crowther
    St Joseph s Hospital, Hamilton, Ontario, Canada
    Crit Care 10:150. 2006
    ..These findings provide reassurance that subcutaneously administered medications may be used in critically ill patients with edema...
  28. ncbi request reprint Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study
    Deborah J Cook
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    J Crit Care 20:364-72. 2005
    ..Its additional goals were to evaluate the suitability of the exclusion criteria and to document the range of research activities that precede accrual of patients into a trial to plan multisite management...
  29. ncbi request reprint Direct thrombin inhibitors
    Jeffrey I Weitz
    McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3
    Thromb Res 106:V275-84. 2002
    ..This review summarizes the clinical trial data with direct thrombin inhibitors and provides perspective on the role of direct thrombin inhibitors in the face of other new anticoagulants currently under development...